Tumour SNPs associated with immune‑related hepatitis in patients with melanoma receiving immune checkpoint inhibitors

Thumbnail Image

Files

Artículo Biomedicines.pdf (255.17 KB)
Identifiers
URI: https://hdl.handle.net/11268/16410
DOI: 10.3390/biomedicines13102351

Publication date

2025

Authors

Rodríguez Piñas, José María

Advisors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

SDG

goal-3
goal-4
goal-9

Metrics

Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

Immune checkpoint inhibitors (ICIs) have significantly improved survival rates for patients with metastatic melanoma. However, these treatments can lead to immune-related adverse events (irAEs), including hepatitis. This exploratory study sought to identify tumour single-nucleotide polymorphisms (SNPs) associated with the risk of ICI-induced hepatitis in melanomapatients. This exploratory study identifies candidate tumour SNPs as possible biomarkers to predict the risk of ICI-induced hepatitis, warranting their validation in larger patient cohorts.

Description

UNESCO Subjects

Ciencias médicas
Genética humana
Medicina clínica

Keywords

Bibliographic reference

Jose María Rodríguez-Piñas, Alicia Romero-Lorca, María Gaibar, Apolonia Novillo, Margarita Rubio, Diego Malon, Beatriz Antón-Pascual, Francisca Inmaculada Camacho, Mercedes Cavanagh, David Ricardo Lujan Rodriguez, Ana Manuela Martín, Radia Khedaoui, Diana Moreno, Fernando Javier Pinedo, Macarena Boiza, Silvia García, Patricia Gómez, David Marrupe, Ana Fernández-Santander. Tumour SNPs associated with immune‑related hepatitis in patients with melanoma receiving immune checkpoint inhibitors. (2025). Biomedicines. 13(10), 2351. https://doi.org/10.3390/biomedicines13102351
Editor's version
http://doi.org/10.3390/biomedicines13102351

Type of document

journal article

Collections

Área de Ciencias de la Salud
Attribution 4.0 International

La licencia de este ítem se describe como Attribution 4.0 International